


**AMENDMENTS TO THE CLAIMS**

Please cancel claims 46 and 48, and add new claims 54-74. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-53. (Canceled)

54. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein  $\text{R}^1$  and  $\text{R}^3$  are each independently selected from the group consisting of  $\text{C}_1$ - $\text{C}_{20}$  substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic,

wherein substituents for alkyl and cycloalkyl are selected from the group consisting of -halogen, -OR', -NR'R'', -SR', -OC(O)R', -C(O)R', -CO<sub>2</sub>R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)<sub>2</sub>R', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R'', -CN, -NO<sub>2</sub>, =O, =NR', and =N-OR',

wherein substituents for aryl and heteroaryl are selected from the group consisting of -halogen, -OR', -NR'R'', -SR', -OC(O)R', -C(O)R', -CO<sub>2</sub>R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)<sub>2</sub>R', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R'', -CN, -NO<sub>2</sub>, -R', -N<sub>3</sub>, -CH(Ph)<sub>2</sub>, perfluoro( $\text{C}_1$ - $\text{C}_4$ )alkoxy, and perfluoro( $\text{C}_1$ - $\text{C}_4$ )alkyl,

wherein R', R'' and R''' each independently refer to hydrogen, unsubstituted ( $\text{C}_1$ - $\text{C}_8$ )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl,

alkoxy or thioalkoxy groups, or aryl-(C<sub>1</sub>-C<sub>4</sub>)alkyl groups, thereby reducing blood pressure in the patient.

55. (New): The method of claim 54, wherein the patient is a human.

56. (New): The method of claim 54, wherein the patient has hypertension.

57. (New): The method of claim 54, wherein blood pressure reduction comprises a reduction in systolic blood pressure.

58. (New): The method of claim 54, wherein the patient has high normal blood pressure.

59. (New): The method of claim 54, wherein the patient is at risk for cardiovascular disease, renal disease or stroke.


60. (New): The method of claim 54, wherein the patient has cardiovascular disease or renal disease.

61. (New): The method of claim 54, wherein the inhibitor is administered orally.

62. (New): The method of claim 54, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC<sub>50</sub> of less than 500 μM.

63. (New): The method of claim 54, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC<sub>50</sub> of less than 17.8 μM.


64. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein R<sup>1</sup> and R<sup>3</sup> are each independently selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic, wherein at least one of R<sup>1</sup> and R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl and cycloalkyl, thereby reducing blood pressure in the patient.

- 65. (New): The method of claim 64, wherein the patient is a human.
- 66. (New): The method of claim 64, wherein the patient has hypertension.
- 67. (New): The method of claim 64, wherein blood pressure reduction comprises a reduction in systolic blood pressure.
- 68. (New): The method of claim 64, wherein the patient has high normal blood pressure.
- 69. (New): The method of claim 64, wherein the patient is at risk for cardiovascular disease, renal disease or stroke.
- 70. (New): The method of claim 64, wherein the patient has cardiovascular disease or renal disease.
- 71. (New): The method of claim 64, wherein the inhibitor is administered orally.
- 72. (New): The method of claim 64, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC<sub>50</sub> of less than 500 μM.
- 73. (New): The method of claim 64, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC<sub>50</sub> of less than 17.8 μM.

74. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein R<sup>1</sup> and R<sup>3</sup> are each independently selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic, wherein when R<sup>1</sup> is aryl, then R<sup>3</sup> is other than heteroaryl and aryl, thereby reducing blood pressure in the patient.